Turning Point Therapeutics TPTX

$ 75.16 -0.13%

Quarterly report 2022-Q2
added 08-08-2022

Turning Point Therapeutics Financial Statements 2011-2024 | TPTX

Annual Financial Statements Turning Point Therapeutics

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	2.32 B	5.29 B	1.46 B	-	-	-	-	-	-	-	-
Shares	49.3 M	42.2 M	24.1 M	-	-	-	-	-	-	-	-
Historical Prices	47.7	122	62.3	-	-	-	-	-	-	-	-
Net Income	-237 M	-157 M	-72.1 M	-24.8 M	-16.6 M	-	-	-	-	-	-
Revenue	30.8 M	25 M	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	25	-	-	-	-	-	-	-	-	-
Operating Income	-238 M	-162 M	-77.7 M	-25.6 M	-16.7 M	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-237 M	-159 M	-76.1 M	-25.5 M	-16.7 M	-	-	-	-	-	-
Operating Expenses	269 M	187 M	77.7 M	-	-	-	-	-	-	-	-
General and Administrative Expenses	75.8 M	73.4 M	19.8 M	4.58 M	1.49 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Turning Point Therapeutics

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	-	-	49.7 M	49.6 M	49.6 M	49.4 M	49.2 M	48.9 M	46.6 M	42.2 M	38.6 M	35.9 M	35.9 M	32.3 M	24.5 M	3.41 M	3.41 M	3.39 M	3.38 M	3.37 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-123 M	-74.4 M	-	-66.3 M	-56.3 M	-35.5 M	-47.4 M	-17.7 M	-31.5 M	-60.7 M	-21 M	-20.5 M	-17.1 M	-13.5 M	-9.02 M	-6 M	-5.04 M	-4.73 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	119 K	429 K	-	460 K	5.16 M	25.2 M	-	25 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-124 M	-74.9 M	-	-66.7 M	-56.7 M	-36 M	-47.9 M	-18.5 M	-32.7 M	-62.6 M	-23.1 M	-22.1 M	-18.5 M	-14.1 M	-9.48 M	-6.13 M	-5.17 M	-4.86 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	1.66 M	1.31 M	518 K	-	132 K	135 K	127 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-124 M	-74.5 M	-	-66.4 M	-56.4 M	-35.8 M	-47.9 M	-18.3 M	-32.5 M	-62.4 M	-23.1 M	-22 M	-18.4 M	-14 M	-9.48 M	-6.1 M	-5.15 M	-4.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	124 M	75.4 M	-	67.1 M	61.8 M	61.3 M	-	43.5 M	32.7 M	62.6 M	-	22.1 M	18.5 M	14.1 M	-	6.13 M	5.17 M	4.86 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	-	-	37.7 M	20.3 M	-	18.2 M	17.2 M	20 M	-	11.3 M	8.58 M	39.9 M	-	5.5 M	4.74 M	3.61 M	-	1 M	803 K	516 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency